CollPlant Biotechnologies (CLGN) Gross Margin (2017 - 2026)
CollPlant Biotechnologies (CLGN) posted Gross Margin of 332.88% for Q1 2026, down 51.31% on a QoQ basis from 220.0% in Q4 2025, and down 42373.0% year-over-year from N/an in Q1 2025.
CollPlant Biotechnologies (CLGN) Gross Margin (2017 - 2026) Analysis & Trends
CollPlant Biotechnologies' Gross Margin history runs 10 years deep, the most recent figure standing at 332.88% for Q1 2026.
- Quarterly Gross Margin fell 42373.0% year-over-year to 332.88% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1799631.62% (down 179968033.0% YoY) and the FY2025 annual result came in at 64.78%, up 28032.0% from the prior year.
- Gross Margin was 332.88% for Q1 2026 at CollPlant Biotechnologies, down from 220.0% in the prior quarter.
- Across five years, Gross Margin topped out at 93.96% in Q2 2023 and bottomed at 3910614.53% in Q2 2025.
- A 5-year average of 244926.06% and a median of 128.73% in 2022 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2022 — Gross Margin soared 142842923 bps — and 2025, when it tumbled 391049926 bps.
- CollPlant Biotechnologies' Gross Margin stood at 6.9% in 2022, then plunged by 2199 bps to 158.53% in 2023, then surged by 58 bps to 65.85% in 2024, then sank by 234 bps to 220.0% in 2025, then plunged by 51 bps to 332.88% in 2026.
- Business Quant data shows CLGN's Gross Margin at 332.88% in Q1 2026, 220.0% in Q4 2025, and 249.35% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 88.95% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 86.85% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 91.79% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 90.68% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | CollPlant Biotechnologies | 4.63 Mn | 4.63 Mn | -243,000.00 | -332.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 30, 2026 | -332.88% |
| Dec 31, 2025 | -220.00% |
| Sep 30, 2025 | -249.35% |
| Jun 30, 2025 | -3,910,614.53% |
| Mar 30, 2025 | 90.85% |
| Dec 31, 2024 | -65.85% |
| Sep 30, 2024 | -6,700.00% |
| Jun 30, 2024 | -115.26% |
| Mar 31, 2024 | -456.12% |
| Dec 31, 2023 | -158.53% |
| Sep 30, 2023 | 0.00% |
| Jun 30, 2023 | 93.96% |
| Mar 31, 2023 | 24.94% |
| Dec 31, 2022 | -6.90% |
| Sep 30, 2022 | -142.20% |
| Jun 30, 2022 | 34.85% |
| Dec 31, 2021 | -76.77% |
| Sep 30, 2021 | -1,428,571.43% |
| Jun 30, 2021 | 37.92% |
| Mar 31, 2021 | 93.89% |